# Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

> **NCT06834971** · NA · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 508 (estimated)

## Conditions studied

- Ventilator-Associated Pneumonia (VAP)

## Interventions

- **DRUG:** Colistimethate sodium (CMS)

## Key facts

- **NCT ID:** NCT06834971
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 508 (ESTIMATED)
- **Last updated:** 2025-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834971, "Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06834971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*